key: cord-0060506-mxumrvh6
authors: Medranda, Giorgio A.; Case, Brian C.; Wermers, Jason P.; Morrison, Natalie; Waksman, Ron
title: Review of late-breaking trials from CRT 2021 virtual
date: 2021-03-23
journal: Cardiovasc Revasc Med
DOI: 10.1016/j.carrev.2021.03.016
sha: 5cba8768ca71ea0da6cc54f511cecb9d71b3a9b5
doc_id: 60506
cord_uid: mxumrvh6

nan

Since March 2020, the coronavirus disease 2019 (COVID-19) pandemic has redefined the way in which cardiology conferences have been held. Cardiovascular Research Technologies (CRT) 2020 was the last in-person cardiology meeting in 2020 just before the outbreak of COVID-19 in the U.S. Nearly a year later, given the continued presence of COVID-19, CRT 2021 transitioned into a fully virtual meeting. In this article, we present a brief overview of late-breaking clinical trials presented at CRT 2021 Virtual. the catheter devices used to lacerate aortic valve leaflets in the BASILICA procedure, which was in turn developed by the NIH. While rareoccurring in just 0.7% of TAVR casescoronary artery obstruction is a "devastating" complication with suboptimal preventative strategies, Khan and colleagues noted in 2019 when results from the prospective multicenter BASILICA trial (enrolled in 2018) were first reported [3] .

Coronary obstruction has a 40% to 50% mortality rate, Khan said, as he reported new findings from a larger cohort of 214 patients. These patients were enrolled between June 2017 and December 2020 across sites in North America and Europe. The retrospective, multicenter, single-arm registry study was aimed at determining the safety of the procedure and its feasibility in a real-world settingdata that were previously lacking. The new study included patients who had received BASILICA to prevent coronary artery obstruction but excluded patients from the existing BASILICA trial.

Patients in the registry had a mean age of 74.9±10.6 years, 68.7% were women, and the majority (54%) were considered high-risk. Aortic stenosis (AS) was present for 85.9% and aortic regurgitation (AR) in 14.1%. During TAVR procedures, 60.1% received a SAPIEN 3 (Edwards laceration in 94.4%, no culprit coronary obstruction found for 95.3% of cases, and no emergency surgery or re-intervention for 93%. There was a 100% procedural survival rate.

Valve Academic Research Consortium-2 (VARC-2) definitions were used to adjudicate events.

At 30 days, 5.7% of patients had coronary obstruction, including non-culprit obstructions, while just 2.8% died. Stroke occurred in 2.8% (0.5% of which were disabling), 3.3% had a lifethreatening bleed, 3.8% had a major vascular complication, and 4.3% had acute kidney injury. The study demonstrated that BASILICA is safe, with low rates of stroke and death, said Khan.

He added that more importantly, the study demonstrates the BASILICA procedure to be safe in a real-world setting in centers with appropriate training, leading to high rates of success and low rates of coronary artery obstruction. heart valves, those who received DOACs were older (mean age 60.8 years vs. 53.0 years) and had a higher prevalence of comorbiditiesincluding hypertension (83% vs. 68%), arrhythmia (47% vs. 30%) and peripheral arterial disease (18% vs. 7%). They were more likely to have been on a DOAC preoperatively compared to the mechanical-heart-valve patients who received warfarin. Patients with bioprosthetic heart valves who received DOACs were also older (mean age 66.3 years vs. 65.0 years), had a higher prevalence of co-morbiditiesparticularly arrhythmia (90% vs. 42%)and had a higher percentage of DOAC use preoperatively than those given warfarin. Prosthetic valve patients receiving DOAC had higher post-operative (before discharge) incidence rates, such as pulmonary embolism -1.1% for mechanical valve patients given DOAC vs. 0.04% for those given warfarin, and 0.37% for DOAC bioprosthetic valve "However, these dimensions alone are poor discriminators for coronary obstruction," Khan noted. He stressed that cusp height greater than or equal to coronary height appears to be an important mechanism for obstruction, with 96.6% sensitivity. A VTC of less than 4 mm or calcium volume over 600 mm 3 also had 95.6% sensitivity for coronary obstruction, he concluded.

TAVR is approved for low-risk tricuspid patients in the US; however, data on TAVR in low-risk patients with severe bicuspid AS are lacking. The bicuspid registry of the LRT trial sought to elucidate the safety and efficacy of TAVR in these patients. The results were presented by investigator Toby Rogers, MD, PhD, of MedStar Washington Hospital Center and the NHLBI [6] . Bicuspid patients were excluded from the LRT trial, but the trial's bicuspid registry Rogers drew comparisons with tricuspid patients, noting that those with bicuspid AS tended to be younger, but that the subclinical leaflet thrombosis rate was found to be similar between the two groups. Finally, only a minority of patients in the bicuspid analysis had Sievers Type 0 morphology (no raphe), he added; thus, the results of this trial could not be applied to patients with Sievers Type 0 anatomy. A specific BVS implantation technique has never been employed from the start in previous randomized clinical trials for the Absorb device. COMPARE-ABSORBa trial with grant funding from Abbott, the manufacturer of both devices in the trialwas therefore launched with a dedicated optimal implantation technique for BVS, which includes mandatory pre-dilation with 1:1 balloon-artery ratio and high pressure (>16 atm) post-dilation. The findings from the COMPARE-ABSORB trial were presented by principal investigator Pieter C. Smits, MD, of Maasstad Hospital Rotterdam, Netherlands [10] . Treatment of target vessels less than 2.75 mm measured by quantitative coronary arteriography (QCA), intravascular ultrasound (IVUS) or optical coherence tomography (OCT), and post-dilation with non-compliant (NC) balloons up to 0.5 mm larger than the scaffold are also recommended. The hypothesis was that, after full resorption, the BVS procedure could lead to better long-term outcomes for a high-risk population for restenosis compared to PCI with the metallic DES.

In order to find the patient population that could potentially benefit most from the vascular restoration therapy concept in the long term, the patient selection included those with complex colchicine compared to 12 (7.5%) on placebo (p = 0.23), and occurred in 15 (9.3%) and 18 (11.2%) at 1 year, respectively (p = 0.54). By 48 hours, mean troponin was 1197 ng/ml for those in the treatment arm, compared to 1147 ng/ml in placebo (p = 0.88), and hs-CRP was 176.5 mg/L vs. 244.5 mg/L (p = 0.39). P-selectin at 24 hours was a mean of 95 ng/ml vs. 99 ng/ml (p = 0.99).

Jenab concluded that the study shows increased CRP at 48 hours in the colchicine group was less than that in the placebo group, but the difference was not significant.

"Therefore the study trend was toward the potential benefit for colchicine," he said. The relatively small sample size precludes robust conclusions concerning the study's primary outcome, he added.

J o u r n a l P r e -p r o o f

large randomized study, introducing shortened DAPT in troponin negative patients alongside a "considerable population

all-comer" population through 3-year postimplantation follow-up. TLF was defined as a composite of cardiac death, target-vessel myocardial infarction and target-lesion revascularization

DAPT duration was similar in both arms, with 12 months in troponin-positive patients and 1 month in troponin-negative patients. Cardiac death occurred in 11 (1.5%) of PP-ZES patients vs

All patients were also treated with routine medications for acute MI, including 300 mg of aspirin, 600 mg of clopidogrel, and 80 mg of atorvastatin. The NRP primary endpoint was defined as Thrombolysis in Myocardial Infarction (TIMI) flow grade of less than 3 after PCI, or -if the TIMI flow grade was 3 -TIMI flow grade after PCI of zero or 1. Secondary endpoints included major adverse cardiovascular events (MACE) at 1 month and 1 year, ST-segment resolution (STR), high sensitivity (hs) troponin T at baseline, 24 hours, and 48 hours after PCI, P-selectin at baseline and 24 hours

years, 32.9% of colchicine patients with diabetes mellitus vs. 38.1% of control patients, and 40.4% of the colchicine group with hypertension vs. 38.8% of the control group. Pain-to-device time was 235 minutes for the colchicine group vs. 265 minutes for the control. The mean stent lesion length was 12.75 mm for the treatment group and 13.15 mm for placebo, and respectively

3%) in the control group (p = 0.32). MACE at 1 month occurred in seven

Clinical Outcomes After BASILICA and TAVR in 214 Patients

Preventing Coronary Obstruction during Transcatheter Aortic Valve Replacement: Results from the

The BASILICA Trial: Prospective Multicenter Investigation of Intentional Leaflet Laceration to Prevent TAVR Coronary Obstruction

Use of Direct Oral Anticoagulants in Patients Receiving Mechanical and Bioprosthetic Heart Valves: Insights From the Society of Thoracic Surgeons National Database

Coronary Obstruction From TAVR in Native Aortic Stenosis: Anatomic Predictors From Two Large Global Registries

TAVR in Low Risk Patients with Bicuspid Aortic Stenosis: 1-Year Results from the LRT Trial

Randomized Comparison of Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial J o u r n a l P r e -p r o o f Infarction: Final 2-Year Outcomes of the BIOSTEMI Randomized Trial

Biodegradable-Versus Durable-Polymer Drug-Eluting Stents for STEMI

Biodegradable-Versus Durable-Polymer DES in ST-Segment Elevation Myocardial Infarction

3-Year Results From the COMPARE ABSORB Trial

ABSORB Bioresorbable Scaffold vs. Xience Metallic Stent for Prevention of Restenosis in Patients at High Risk of Restenosis (Compare Absorb)

Three-Year Clinical Outcomes After Implantation of a Permanent-Polymer Zotarolimus

Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent: Landmark Analysis of the